These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29902087)

  • 1. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
    Cazzaniga ME; Munzone E; Montagna E; Pappagallo G
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):805-814. PubMed ID: 29902087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
    Xu B; Sun T; Wang S; Lin Y
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):71-79. PubMed ID: 33054438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
    Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A
    Breast Cancer Res; 2019 Sep; 21(1):108. PubMed ID: 31533777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.
    Krajnak S; Decker T; Schollenberger L; Rosé C; Ruckes C; Fehm T; Thomssen C; Harbeck N; Schmidt M
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3391-3400. PubMed ID: 33743073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
    De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
    Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
    Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
    Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis.
    Xu K; Liu T; Zhang J; Zhou Y; Yang F; Ren T
    Int J Clin Oncol; 2020 Sep; 25(9):1624-1634. PubMed ID: 32472208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
    Mencoboni M; Filiberti RA; Taveggia P; Del Corso L; Del Conte A; Covesnon MG; Puccetti C; Donati S; Auriati L; Amoroso D; Camerini A
    Anticancer Res; 2017 Jun; 37(6):3189-3194. PubMed ID: 28551663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
    Pasini F; Barile C; Caruso D; Modena Y; Fraccon AP; Bertolaso L; Menon D; La Russa F; Crepaldi G; Bononi A; Spezzano R; Padrini R; Corona G; Gusella M
    Invest New Drugs; 2018 Oct; 36(5):927-932. PubMed ID: 29956056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.
    Cazzaniga ME; Munzone E; Bocci G; Afonso N; Gomez P; Langkjer S; Petru E; Pivot X; Sánchez Rovira P; Wysocki P; Torri V
    Adv Ther; 2019 Feb; 36(2):381-406. PubMed ID: 30565179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.
    Sanna G; Pestrin M; Moretti E; Biagioni C; De Santo I; Gabellini S; Galardi F; McCartney A; Biganzoli L
    Clin Breast Cancer; 2021 Aug; 21(4):e332-e339. PubMed ID: 33353853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.
    Langkjer ST; Kenholm J; Jensen JD; Wedervang K; Brixen AT; Grunnet M; Stenbygaard L; Gilje B; Danø H; Glavicic V; Jacobsen EH; Brems-Eskildsen AS; Kruse HL; Dongsgaard T; Neimann J; Geisler J
    Future Oncol; 2019 Aug; 15(22):2561-2569. PubMed ID: 31215242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
    Addeo R; Sgambato A; Cennamo G; Montella L; Faiola V; Abbruzzese A; Capasso E; Leo L; Botti G; Caraglia M; Del Prete S
    Clin Breast Cancer; 2010 Aug; 10(4):301-6. PubMed ID: 20705563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
    Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
    BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.].
    Ghilardi M
    Recenti Prog Med; 2019 Oct; 110(10):490-493. PubMed ID: 31657815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
    Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.